<DOC>
	<DOCNO>NCT01679119</DOCNO>
	<brief_summary>The purpose trial compare efficacy safety Inotuzumab Ozogamicin combination R-CVP R-G-CVP treatment Diffuse Large B Cell Lymphoma ( DLBCL ) population patient suitable anthracycline base chemotherapy . There standard care treatment group patient . If demonstrate efficacious safe deliver regimen test phase III trial determine whether become standard care amongst patient DLBCL fit anthracycline ( R-CHOP ) .</brief_summary>
	<brief_title>Treatment Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable Anthracycline Containing Chemotherapy</brief_title>
	<detailed_description>The incidence DLBCL increase expand elderly population , incidence continue rise . Given 40 % case DLBCL occur patient age 70 number co-mobilities increase age , research investigate optimal treatment DLBCL group patient need . R-CHOP remain standard care majority patient DLBCL , anthracycline use preclude proportion patient high risk develop cardiotoxicity , especially congestive cardiac failure . Currently standard care patient unfit anthracycline treatment . It routine omit doxorubicin R-CHOP , give R-CVP instead . However outcome patient treat R-CVP poor attempt make replace doxorubicin alternative agent . The trial compare experimental arm consist Inotuzumab Ozogamicin add standard immunochemotherapy regimen rituximab , cyclophosphamide , vincristine prednisolone ( R-CVP ) control arm gemcitabine add combination ( Gem-R-CVP ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion criterion : Informed write consent trial Histologically proven diffuse large B cell lymphoma ( DLBCL ) accord current World Health Organisation ( WHO ) classification include morphological variant . The B cell nature proliferation must verify demonstration CD20 positivity . A concurrent ( synchronous ) diagnosis low grade lymphoma ( e.g . bone marrow trephine presence low grade DLBCL lymph node biopsy ) permit Bulky Stage IA ( lymph node lymph node mass ≥ 10cm maximum diameter ) , stage IB , stage II , stage III stage IV disease ECOG performance status 02 Measurable disease Age 18 ≥ year Adequate contraceptive precaution patient childbearing potential No active malignant disease nonmelanotic skin cancer , superficial bladder cancer carcinoma insitu uterine cervix last 5 year No previous chemotherapy , radiotherapy investigational drug indication previous corticosteroid dose equivalent prednisolone 1mg/kg/day 14 day permit prior randomisation EITHER Unsuitable anthracyclinecontaining chemotherapy due impaired cardiac function define ejection fraction ≤ 50 % OR Left ventricle ejection fraction &gt; 50 % presence significant comorbidities ( diabetes mellitus , hypertension ischaemic heart disease ) preclude anthracyclinecontaining chemotherapy determine treat physician . Comorbidities must document randomisation form CIRS score record Adequate bone marrow function ( Platelets &gt; 100x109/l , WBC &gt; 3.0x109/l , Neutrophils &gt; 1.5x109/l ) time study entry unless attribute bone marrow infiltration DLBCL Life expectancy &gt; 3 month Exclusion criterion : Symptomatic central nervous system meningeal involvement DLBCL Previous diagnosis low grade lymphoma . Nonbulky stage IA disease ECOG performance status 34 History chronic liver disease suspect alcohol abuse Serum bilirubin great upper limit normal unless attributable Gilberts syndrome haemolysis Alanine and/or aspartate aminotransferase level ( ALT and/or AST ) alkaline phosphatase ( ALP ) great 2.5 time upper limit normal Glomerular filtration rate ( GFR ) &lt; 30ml/min . GFR calculate CockroftGault ( eGFR ) . Serological evidence active hepatitis B C infection whether acute chronic ( define positive antiHCV serology ; positive HBsAg ) . All positive HBcAb result also exclude safety ground regardless HBsAg HBV DNA status . Antibodies Hepatitis B surface antigen ( antiHBs ) due history past vaccination acceptable Known history HIV seropositive status Patients history Venoocclusive Disease ( VOD ) Sinusoidal Obstructive Syndrome ( SOS ) Patients screen QTcF interval &gt; 470msec Medical psychiatric condition compromise patient 's ability give inform consent Women pregnant lactate LVEF &gt; 50 % absence significant comorbidities preclude anthracycline use Patients history severe allergic/anaphylactic reaction humanise monoclonal antibody Patients serious active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Diffuse large b cell lymphoma</keyword>
	<keyword>Inotuzumab Ozogamicin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisolone</keyword>
</DOC>